- Home
- FHI vs PRCT Comparison
FHI vs PRCT Comparison
Compare FHI & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHI
- PRCT
- Stock Information
- Founded
- FHI 1955
- PRCT 2009
- Country
- FHI United States
- PRCT United States
- Employees
- FHI N/A
- PRCT N/A
- Industry
- FHI Investment Managers
- PRCT Medical Specialities
- Sector
- FHI Finance
- PRCT Health Care
- Exchange
- FHI Nasdaq
- PRCT Nasdaq
- Market Cap
- FHI 3.1B
- PRCT 2.9B
- IPO Year
- FHI N/A
- PRCT 2021
- Fundamental
- Price
- FHI $42.78
- PRCT $53.12
- Analyst Decision
- FHI Hold
- PRCT Strong Buy
- Analyst Count
- FHI 6
- PRCT 7
- Target Price
- FHI $42.33
- PRCT $90.00
- AVG Volume (30 Days)
- FHI 844.1K
- PRCT 1.1M
- Earning Date
- FHI 04-24-2025
- PRCT 04-24-2025
- Dividend Yield
- FHI 3.17%
- PRCT N/A
- EPS Growth
- FHI 2.09
- PRCT N/A
- EPS
- FHI 3.58
- PRCT N/A
- Revenue
- FHI $1,659,262,000.00
- PRCT $249,121,000.00
- Revenue This Year
- FHI $6.24
- PRCT $46.28
- Revenue Next Year
- FHI $3.75
- PRCT $32.67
- P/E Ratio
- FHI $11.97
- PRCT N/A
- Revenue Growth
- FHI 2.19
- PRCT 59.36
- 52 Week Low
- FHI $31.24
- PRCT $47.04
- 52 Week High
- FHI $43.92
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- FHI 68.97
- PRCT 46.17
- Support Level
- FHI $41.04
- PRCT $52.43
- Resistance Level
- FHI $40.66
- PRCT $56.29
- Average True Range (ATR)
- FHI 0.92
- PRCT 2.88
- MACD
- FHI 0.42
- PRCT 0.28
- Stochastic Oscillator
- FHI 96.80
- PRCT 48.53
About FHI Federated Hermes Inc.
ederated provides asset management services for institutional and individual investors. The company had $757.6 billion in managed assets at the end of December 2023, composed of equity (10%), multi-asset (less than 1%), fixed-income (13%), alternative (3%), and money market (74%) funds. That said, the firm's cash-management operations are expected to generate around 46% of Federated's revenue this year, compared with 29%, 13%, and 11%, respectively, for the firm's equity, fixed-income, and alternatives/multi-asset operations. From a channel perspective, the company's products are distributed via trust banks, wealth managers and retail broker/dealers (63% of AUM), institutional investors (28%), and international clients (9%).
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.